$1.84
-2.9%Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.
Last Annual Value
9.85M
3-Year CAGR
-2%
5-Year CAGR
25%
10-Year CAGR
22%
| Company | Stock Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Stereotaxis, Inc. AMEX:STXS | 9.85M | -2.5% | 1.0% | 21.9% | |
![]() CVRx, Inc. NASDAQ:CVRX | 11.05M | 20.6% | 42.0% | N/A | |
![]() Exagen Inc. NASDAQ:XGN | 2.16M | -15.8% | -14.5% | N/A | |
![]() OraSure Technologies, Inc. NASDAQ:OSUR | 10.15K | -90.2% | -73.5% | -47.2% | |
![]() Quanterix Corporation NASDAQ:QTRX | 20.72M | 7.3% | 5.3% | 36.4% | |
![]() Sanara MedTech Inc. NASDAQ:SMTI | 718.71K | -40.7% | -23.1% | -1.2% | |
![]() Humacyte, Inc. NASDAQ:HUMA | 9.75M | 12.6% | -0.8% | N/A | |
![]() Sagimet Biosciences Inc. NASDAQ:SGMT | 6.45M | 8.9% | 27.6% | N/A | |
![]() NeoGenomics, Inc. NASDAQ:NEO | 41.32M | 18.8% | 13.0% | 22.5% | |
![]() Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 25.41M | -9.8% | -2.6% | 26.1% |
Continue your STXS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.